Lanreotide + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoid Syndrome
Conditions
Carcinoid Syndrome
Trial Timeline
May 1, 2009 → Dec 1, 2015
NCT ID
NCT00774930About Lanreotide + Placebo
Lanreotide + Placebo is a phase 3 stage product being developed by Ipsen for Carcinoid Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00774930. Target conditions include Carcinoid Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00774930 | Phase 3 | Completed |
Competing Products
20 competing products in Carcinoid Syndrome